Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 268

Similar articles for PubMed (Select 21997849)

1.

Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.

Liu YC, Lu PL, Hsiao HH, Chang CS, Liu TC, Yang WC, Lin SF.

Ann Hematol. 2012 Apr;91(4):587-95. doi: 10.1007/s00277-011-1351-8. Epub 2011 Oct 15.

PMID:
21997849
2.

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.

George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.

Transpl Infect Dis. 2010 Aug 1;12(4):322-9. doi: 10.1111/j.1399-3062.2010.00504.x. Epub 2010 May 11.

PMID:
20487414
3.

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA.

Biol Blood Marrow Transplant. 2001;7(6):343-51.

PMID:
11464977
5.

Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.

Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ.

Transplantation. 2002 Jul 15;74(1):49-54.

PMID:
12134098
6.

Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.

Almyroudis NG, Jakubowski A, Jaffe D, Sepkowitz K, Pamer E, O'Reilly RJ, Papanicolaou GA.

Transpl Infect Dis. 2007 Dec;9(4):286-94. Epub 2007 May 19.

PMID:
17511819
7.

Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation.

Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM.

Biol Blood Marrow Transplant. 2009 Sep;15(9):1049-59. doi: 10.1016/j.bbmt.2009.05.001. Epub 2009 Jun 26.

8.

Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.

Piñana JL, Martino R, Barba P, Margall N, Roig MC, Valcárcel D, Sierra J, Rabella N.

Bone Marrow Transplant. 2010 Mar;45(3):534-42. doi: 10.1038/bmt.2009.180. Epub 2009 Aug 10.

PMID:
19668235
9.
10.

[Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].

Huang XJ, Xu LP, Ren HY, Zhang YC, Guo NL, Lu DP.

Zhonghua Yi Xue Za Zhi. 2003 May 10;83(9):766-9. Chinese.

PMID:
12899755
11.

[Risk factors of cytomegalovirus infection and antiviral efficacy in recipients of hematopoietic stem cell transplantation].

Ding H, Ren H, Guo N, Huang X, Xu L, Zhang Y, Lu D.

Beijing Da Xue Xue Bao. 2003 Dec 18;35(6):596-9. Chinese.

12.

[Prevalence of human herpesvirus-6 in allogeneic hematopoietic stem cell transplant recipients in correlation with cytomegalovirus infection].

Wang LR, Dong LJ, Lu DP.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Dec;14(6):1204-9. Chinese.

PMID:
17204195
13.

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L.

Blood. 2003 Jan 15;101(2):407-14. Epub 2002 Sep 12.

14.

Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation.

Wang LR, Dong LJ, Zhang MJ, Lu DP.

Bone Marrow Transplant. 2008 Nov;42(10):673-7. doi: 10.1038/bmt.2008.238. Epub 2008 Aug 11.

PMID:
18695666
15.

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.

Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, Zhang Y, Liu C, Sun J, Liu Q.

J Hematol Oncol. 2012 Aug 2;5:46. doi: 10.1186/1756-8722-5-46.

16.

[Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].

Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XS, Yu L, Han W, Zhang XH, Wang Y, Chen Y, Huang XJ.

Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81. Chinese.

PMID:
19563015
17.

Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.

Schetelig J, Oswald O, Steuer N, Radonic A, Thulke S, Held TK, Oertel J, Nitsche A, Siegert W.

Bone Marrow Transplant. 2003 Oct;32(7):695-701.

PMID:
13130317
18.

[Surveillance of cytomegalovirus for antiviral efficacy and risk factors in allogeneic hematopoietic stem cell transplantation].

Jia JS, Liu DP, Huang XJ, Wu T, Liu DH, Zhang YC, Su H, Wang JB, Zhou JR, Liu Q, Ying MY, Sun RJ, Duan X, Lu DP.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Aug;14(4):749-54. Chinese.

PMID:
16928314
19.

Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.

Jaskula E, Dlubek D, Duda D, Bogunia-Kubik K, Mlynarczewska A, Lange A.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1296-305. doi: 10.1016/j.bbmt.2009.06.008. Epub 2009 Aug 8.

20.

Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.

Serio B, Rosamilio R, Giudice V, Pepe S, Zeppa P, Esposiito S, Pezzullo L, Rocco M, Montuori N, Selleri C.

Infez Med. 2012;20 Suppl 2:26-34.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk